55625-40-6

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-quinoline-4-carboxylic acid methyl ester is used as a key intermediate in the synthesis of quinoline-based drugs for various therapeutic applications. Its presence in the molecular structure of these drugs contributes to their pharmacological properties and potential therapeutic effects.
Used in Chemical Industry:
2-Methyl-quinoline-4-carboxylic acid methyl ester is used as a starting material for the preparation of other bioactive molecules and organic compounds. Its reactivity and functional groups make it suitable for various chemical reactions, enabling the synthesis of a wide range of chemical products with diverse applications.
Used in Drug Discovery and Development:
2-Methyl-quinoline-4-carboxylic acid methyl ester is employed as a building block in the design and development of new pharmaceutical compounds. Its unique structure and properties can be exploited to create novel drug candidates with improved efficacy, selectivity, and safety profiles.
Used in Medicinal Chemistry Research:
2-Methyl-quinoline-4-carboxylic acid methyl ester is utilized as a research tool in medicinal chemistry to study the structure-activity relationships of quinoline-based drugs and other bioactive molecules. Its use in chemical synthesis and modification can provide valuable insights into the design and optimization of new drug candidates.

Upstream product

• 186581-53-3 diazomethane 
• 634-38-8 2-methylquinoline-4-carboxylic acid 
• 91-56-5 indole-2,3-dione 
• 67-56-1 methanol 
• 65417-20-1 methyl 2-methylquinoline-4-carboxylate 1-oxide 

Downstream Products

• 4939-28-0 4-(hydroxymethyl)-2-methylquinoline 
• 15821-13-3 2-methylquinoline-4-carboxamide 
• 29620-66-4 2-methylquinoline-4-carboxylic hydrazide 
• 6760-22-1 2-methylquinoline-4-carboxaldehyde 

Relevant academic research and scientific papers

Quinoline substituted chalcone compound as well as preparation method and application thereof

The invention discloses a novel quinoline substituted chalcone compound as well as pharmaceutically acceptable salts and a preparation method thereof. The invention further discloses a pharmaceuticalcomposition which comprises a therapeutically effective amount of the novel quinoline substituted chalcone compound and/or the pharmaceutically acceptable salts and a pharmaceutically acceptable carrier. The invention further discloses a tubulin inhibitor which comprises the novel quinoline substituted chalcone compound and/or the pharmaceutically acceptable salts. The invention further disclosesapplication of the novel quinoline substituted chalcone compound and/or the pharmaceutically acceptable salts in preparing drugs for treating but not limited to colon cancer, leukemia, liver cancer, breast cancer and other diseases. The compound in the application shows excellent anti-tumor activity, and has more stable metabolic properties and better druggability prospect.

Convergent synthesis and cytotoxicity of novel trifluoromethyl-substituted (1H-pyrazol-1-yl)(quinolin-4-yl) methanones

A convergent synthesis of a series of 16 new polysubstituted (5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)(quinolin-4-yl)methanones, starting from isatin and alky(aryl/heteroaryl) ketones, is described. The diheteroaryl methanones were achieved at yields of up to 95% by a [3?+?2] cyclocondensation reaction involving 4-alkyl(aryl/heteroaryl)-4-methoxy-1,1,1-trifluorobut-3-en-2-ones (by two-step reaction) and 2-alkyl(aryl/heteroaryl)-4-carbohydrazides (by three-step reaction). Subsequently, representative dehydrated heterocyclic derivatives were obtained from the respective 5-hydroxy-2-pyrazoline moieties by classical dehydration reactions, which resulted in the corresponding (5-(trifluoromethyl)-1H-pyrazol-1-yl)(quinolin-4-yl)methanones (three examples) at yields of 69–82%. The subsequent cytotoxicity evaluation showed that compounds with aromatic groups at the 2-position of the quinoline and a methyl moiety at the 3-position of the pyrazole have significant cytotoxicity in human leukocytes at high concentrations (200?μM).